The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

Luca Faloppi¹, Maristella Bianconi¹, Riccardo Giampieri¹, Alberto Sobrero², Roberto Labianca³, Daris Ferrari⁴, Sandro Barni⁵, Enrico Aitini⁶, Alberto Zaniboni⁷, Corrado Boni⁸, Francesco Caprioni², Stefania Mosconi³, Silvia Fanello⁶, Rossana Berardi¹, Alessandro Bittoni¹, Kalliopi Andrikou¹, Michela Cinquini⁹, Valter Torri⁹, Mario Scartozzi¹⁰, Stefano Cascinu¹, on behalf of the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

¹Medical Oncology Unit, Università Politecnica delle Marche, AOU “Ospedali Riuniti”, Ancona, Italy
²Medical Oncology Unit, Ospedale S. Martino, Genova, Italy
³Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy
⁴Medical Oncology Unit, Ospedale S. Paolo, Milano, Italy
⁵Medical Oncology Unit, Treviglio Hospital, Treviglio, Italy
⁶Medical Oncology Unit, C. Poma Hospital, Mantova, Italy
⁷Medical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy
⁸Medical Oncology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy
⁹New Drug Development Strategies Laboratory, Mario Negri Institute, Milano, Italy
¹⁰Medical Oncology Unit, Università degli Studi di Cagliari, Azienda Ospedaliero Universitaria, Cagliari, Italy

Correspondence to:
Stefano Cascinu, e-mail: cascinu@yahoo.com

Keywords: pancreatic cancer, lactate dehydrogenase, angiogenesis, sorafenib, TKI

Received: May 22, 2015  Accepted: August 28, 2015  Published: September 10, 2015

ABSTRACT

Although lactate dehydrogenase (LDH) serum levels, indirect markers of angiogenesis, are associated with a worse outcome in several tumours, their prognostic value is not defined in pancreatic cancer. Moreover, high levels are associated even with a lack of efficacy of tyrosine kinase inhibitors, contributing to explain negative results in clinical trials. We assessed the role of LDH in advanced pancreatic cancer receiving sorafenib.

Seventy-one of 114 patients included in the randomised phase II trial MAPS (chemotherapy plus or not sorafenib) and with available serum LDH levels, were included in this analysis. Patients were categorized according to serum LDH levels (LDH ≤vs.> upper normal rate).

A significant difference was found in progression free survival (PFS) and in overall survival (OS) between patients with LDH values under or above the cut-off (PFS: 5.2 vs. 2.7 months, p = 0.0287; OS: 10.7 vs. 5.9 months, p = 0.0021).

After stratification according to LDH serum levels and sorafenib treatment, patients with low LDH serum levels treated with sorafenib showed an advantage in PFS (p = 0.05) and OS (p = 0.0012).

LDH appears to be a reliable parameter to assess the prognosis of advanced pancreatic cancer patients, and it may be a predictive parameter to select patients candidate to receive sorafenib.
INTRODUCTION

A growing body of evidence indicates that hypoxia may promote cancer development and it is involved in the resistance to treatment of cancer cells via the formation of new blood vessels.

Lactate dehydrogenase (LDH), is a key enzyme in the conversion of pyruvate to lactate under anaerobic conditions [1, 2]. The biological link between hypoxia, LDH levels and the tumor-driven angiogenesis pathway through the abnormal activation of the hypoxia inducible factor 1 (HIF-1) is well established. The biological activity of HIF-1 is determined by the expression and activity of the HIF-1α subunit [3]. HIF-1α is an essential factor that up-regulates a series of genes involved in glycolytic energy metabolism, angiogenesis, erythropoiesis and cell survival [4]. Hypoxia in the tumor microenvironment is sufficient to activate HIF-dependent expression of several down-regulated genes [5]. These include genes encoding for vascular endothelial growth factor, erythropoietin and many enzymes involved in glucose, iron, and nucleotide metabolism [6].

The role of hypoxia and how LDH may be useful to identify “hypoxic” tumours has been investigated by our group in colorectal carcinoma and hepatocellular carcinoma [7–9].

Recently, extending our analysis of LDH expression in pancreatic cancer patients, we have retrospectively evaluated the role of this serum marker in a common practice population of 132 advanced pancreatic cancer patients receiving a first line chemotherapy at our institution from 2008 to 2012. Results from this exploratory analysis have shown that LDH serum levels over the upper normal rate (UNR) were associated with poor prognosis in terms progression free survival (PFS) (Figure 1a) and overall survival (OS) (Figure 1b) (Table 1).

Furthermore, in preclinical studies, high levels of LDH were reported to predict resistance to several tyrosine kinase inhibitors (TKI), including sorafenib [10].

Based on these findings, after the encouraging results of our retrospective assessment, we decided to investigate the role of LDH in the phase II randomized trial (MAPS trial) assessing the role of Sorafenib, an anti-angiogenic multitarget TKI, in combination with gemcitabine vs. gemcitabine alone in advanced pancreatic adenocarcinoma in order to find out a possible prognostic and predictive effect of LDH serum levels in this setting [11].

MATERIALS AND METHODS

Patients selection

All patients included in the “MAPS” phase randomized II trial with known LDH values were eligible for our analysis.

For all patients LDH values were collected within one month before the start of chemotherapy. We divided patients according to serum LDH levels in two groups: A: LDH ≤ upper normal rate (UNR) and B: LDH > UNR).

LDH serum levels were determined according to IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) method. The assay has been conducted in Institution Laboratories certified for Quality control according to the present rules in Europe.

The follow-up and evaluation of treatment response protocols, applied in the MAPS phase two study, are summarized below.

Evaluations before and during treatment consisted of a complete medical history and physical examination;

![Figure 1: PFS (a) and OS (b) according to LDH serum values in a common practice population.](image-url) 132 advanced pancreatic cancer patients receiving a first line chemotherapy at our Institution from 2008 to 2012 were analysed. LDH ≤ UNR (99 patients) vs. LDH > UNR (33 patients): PFS 4.3 vs. 2.3 months, \( p = 0.0105 \); OS 8.6 vs. 3.9 months, \( p = 0.0042 \).
assessment of Karnofsky performance status; laboratory tests, including hematological and biochemical tests; CT or MRI of the abdomen or other body areas with disease involvement; and chest radiography or CT scan. Response Evaluation Criteria in Solid Tumors (RECIST) was used for defining response.

Assessments for response at each site were done blindly by a local experienced radiologist who was not directly involved in the trial.

Data validity was checked with periodical monitoring visits at the participating centers by the GISCAD group according to Good Clinical Practice (GCP) recommendations.

**Statistical analysis**

The association between categorical variables was estimated by $\chi^2$ test.

| LDH cut-off | LDH ≤ UNR | LDH > UNR |
|-------------|-----------|-----------|
| No of patients | 98 | 34 |
| Median Age (range) | 65 (38–82) | 62 (44–81) |

| Treatment | $n$ | % | $n$ | % | p |
|-----------|-----|---|-----|---|---|
| Gemcitabine combination | 79 | 81 | 25 | 73 | 0.383 |
| Gemcitabine alone | 19 | 19 | 9 | 27 | |

| Gender | $n$ | % | $n$ | % | p |
|--------|-----|---|-----|---|---|
| Male | 59 | 60 | 21 | 61 | 0.872 |
| Female | 39 | 40 | 13 | 39 | |

| Disease extent | $n$ | % | $n$ | % | p |
|----------------|-----|---|-----|---|---|
| Locally advanced | 27 | 28 | 9 | 27 | 0.902 |
| Metastatic | 71 | 72 | 25 | 73 | |

| Primary tumour location | $n$ | % | $n$ | % | p |
|-------------------------|-----|---|-----|---|---|
| Head | 57 | 58 | 22 | 65 | 0.502 |
| Other | 41 | 42 | 12 | 35 | |

| Biliary stenting | $n$ | % | $n$ | % | p |
|------------------|-----|---|-----|---|---|
| Yes | 12 | 12 | 5 | 15 | 0.712 |
| No | 86 | 88 | 29 | 85 | |

| Metastatic sites location | $n$ | % | $n$ | % | p |
|---------------------------|-----|---|-----|---|---|
| Hepatic | 47 | 48 | 15 | 45 | 0.698 |
| Extra-hepatic | 51 | 52 | 19 | 55 | |

| Metastatic site number | $n$ | % | $n$ | % | p |
|------------------------|-----|---|-----|---|---|
| 1 | 78 | 80 | 24 | 70 | 0.368 |
| 2 | 16 | 16 | 7 | 21 | |
| 3 | 3 | 3 | 1 | 3 | |
| ≥4 | 1 | 1 | 2 | 6 | |

| Karnofsky PS* | $n$ | % | $n$ | % | p |
|---------------|-----|---|-----|---|---|
| <70 | 8 | 8 | 5 | 15 | 0.269 |
| ≥70 | 90 | 92 | 29 | 85 | |

Table 1: Baseline patient characteristics of the common practice population evaluated in our exploratory analysis.
Survival distribution was estimated by the Kaplan–Meier method (Kaplan and Meier, 1958). Significant differences in probability of survival between the strata were evaluated by log-rank test. A significant level of 0.05 was chosen to assess the statistical significance.

For statistical analysis, in both populations, median overall survival (mOS) and median progression free survival (mPFS) were defined as the interval between the date of beginning of treatment to death or last follow-up visit, and to clinical progression or death or last follow-up visit if not progressed.

RESULTS

LDH values were available in 71 out of the 114 MAPS trial enrolled patients. Low LDH serum levels were present in 58 patients while 13 presented high LDH values.

A statistically significant difference was found in PFS (Figure 2a) and in OS (Figure 2b) between patients with LDH values under (58 patients, 82%), or above (13 patients, 18%) the cut-off (group A vs. group B: mPFS 5.2 vs. 2.7 months, HR: 0.52, 95%CI: 0.24–1.11, \( p = 0.0287 \); mOS 10.7 vs 5.9 months, HR: 0.36, 95%CI: 0.13–0.98, \( p = 0.0021 \)).

Stratifying the study population according to LDH serum levels and treatment (chemotherapy plus sorafenib or chemotherapy alone), patients with low LDH serum levels receiving sorafenib showed an advantage in PFS (Figure 3a; sorafenib and LDH ≤ UNR: 31 patients, 44%, 7.6 months; sorafenib and LDH > UNR: 6 patients, 8%, 2.8 months; no sorafenib and LDH ≤ UNR: 27 patients, 38%, 3.3 months; no sorafenib and LDH > UNR: 7 patients, 10%, 2.2 months; \( p = 0.05 \)) and OS (Figure 3b; sorafenib and LDH ≤ UNR: 12.7 months; sorafenib and LDH > UNR: 5.9 months; no sorafenib and LDH ≤ UNR: 8.6 months; no sorafenib and LDH > UNR: 5.2 months; \( p = 0.0012 \)) (Table 2).

The two patients groups proved homogeneous for all the clinical assessed variables (Table 3).

DISCUSSION

In last few years, cytotoxic and “biological” agents have resulted in no meaningful improvements in pancreatic cancer patients’ outcome[12, 13]. Several phase III studies assessing the role of targeted therapies, such as cetuximab [14], bevacizumab [15], erlotinib [16], aflibercept [17], and sorafenib [18], failed to show any significant benefit. One of the reasons of these negative results is the lack of patient selection.

Data from several analyses on different cancers seem to suggest that LDH levels may be a significant prognostic factor.

In colorectal cancer patients, LDH up-regulation was in fact associated with an increased risk of nodal and distant metastases and high LDH serum levels have been shown to correlate with a decreased median overall survival [19, 20].

A strong association between the expression of LDH and an aggressive phenotype has also been demonstrated in gastric cancer [21] and in hepatocellular carcinoma [7, 8, 22].

This apparently enhanced tumor aggressiveness, often determining a worse prognosis in cancer patients whit high LDH levels, have been correlated with molecular mechanisms underlying tumor hypoxia and angiogenesis. This possible link, LDH levels and tumor angiogenesis, has been analyzed in 2 different clinical trials (the CONFIRM 1 & 2 trials) investigating PTK/ZK (vatalanib), an oral VEGFR (vascular endothelial growth factor receptor) inhibitor in advanced colorectal cancer. Both these trials seemed to suggest that angiogenesis

Figure 2: PFS (a) and OS (b) according to LDH serum values in the “MAPS” phase II study population. LDH serum levels under or above the cut-off: PFS 5.2 vs. 2.7 months, \( p = 0.0287 \); OS 10.7 vs 5.9 months, \( p = 0.0021 \).
inhibitors are more effective in patients with high serum LDH levels, confirming the association between this serum marker and tumor angiogenesis [23, 24]. This evidence was confirmed in our work assessing the role of pre-treatment LDH serum levels in colorectal cancer patients receiving a first-line chemotherapy combined with bevacizumab, an anti-angiogenic monoclonal antibody. Bevacizumab showed an advantage in the subgroup of patients with high LDH levels and poor prognosis, confirming the predictive role of LDH in this setting [9]. However, it could be quite different using a TKI inhibitor, such as sorafenib. In fact we recently reported how high LDH serum levels in patients with hepatocellular carcinoma treated with sorafenib are associated with a worse outcome [8].

Based on these considerations, we reanalyzed our MAPS trial in order to evaluate the predictive and prognostic role of LDH serum levels. This analysis confirms the prognostic role of LDH serum levels. Of note, we were also able to show an advantage in PFS and OS in favour of sorafenib in low LDH serum levels, supporting a potential predictive value of LDH even for sorafenib. This clinical findings are supported by a preclinical model, where it has been demonstrated that the inhibition of LDH production with oxamic acid in cancer cell lines potentiated the antiproliferative activity of tyrosine kinase inhibitors, such as sorafenib [10]. The effect of high LDH levels on TKI low activity may be explained by a competition between ATP (adenosine triphosphate) and TKIs inhibition at the ATP enzymatic site on the protein kinases target of their activity.

LDH catalyzed the final step in the glycolytic pathway, the conversion of pyruvate and NADH to lactate and NAD⁺, determining the maintenance of glycolytic flow, and consequently, the production of ATP. In cancer cells, in hypoxic condition, in which anaerobic glycolysis is the main metabolic pathway to meet the energy request, the inhibition of LDH could interfere with this process, causing the depletion of ATP and therefore a lower competition against TKIs inhibitors.

These preclinical findings support our hypothesis about the clinical role of LDH serum levels and are able to contribute to explain the negative results in our MAPS

Table 2: PFS and OS of “MAPS” phase II study population stratified according to LDH serum levels and treatment administered (chemotherapy plus sorafenib or chemotherapy alone)

| Population subgroups | Patients number (%) | PFS (months) | OS (months) |
|----------------------|---------------------|--------------|-------------|
| Sorafenib group      |                     |              |             |
| LDH ≤ UNR            | 31 (44)             | 7.6          | 12.7        |
| LDH > UNR            | 6 (8)               | 2.8          | 5.9         |
| No Sorafenib group   |                     |              |             |
| LDH ≤ UNR            | 27 (38)             | 3.3          | 8.6         |
| LDH > UNR            | 7 (10)              | 2.2          | 5.2         |

\( p = 0.05 \) \( p = 0.0012 \)

Figure 3: PFS (a) and OS (b) according to LDH serum values and treatment administered in the “MAPS” phase II study population. PFS: sorafenib and LDH ≤ UNR: 31 patients, 7.6 months; sorafenib and LDH > UNR: 6 patients, 2.8 months; no sorafenib and LDH ≤ UNR: 27 patients, 3.3 months; no sorafenib and LDH > UNR: 7 patients, 2.2 months; \( p = 0.05 \). OS: sorafenib and LDH ≤ UNR: 12.7 months; sorafenib and LDH > UNR: 5.9 months; no sorafenib and LDH ≤ UNR: 8.6 months; no sorafenib and LDH > UNR: 5.2 months; \( p = 0.0012 \).
trial. Of interest could be a matching analysis of the results of BAYPAN phase III study [18].

The French authors in a similar trial with a comparable number of patients found a negative impact of sorafenib. Reanalyzing this trial according to LDH serum levels could open new perspectives for the use of sorafenib in pancreatic cancer patients.

Likewise data from a reanalysis of the CALGB-80303 phase III trial with bevacizumab could be interesting [15]. In this case we could observe that bevacizumab would be useful in patients with high LDH levels.

Although our study was not preplanned in the design of the MAPS trial and is conducted on a portion of the original cohort of patients, results are promising. Larger perspective studies focusing on LDH role are needed to confirm our findings.

Table 3: Baseline patient characteristics in the subgroup of “MAPS” phase II trial population

| LDH cut-off | LDH ≤ UNR | LDH > UNR |
|-------------|-----------|-----------|
| No of patients (%) | 58 (82) | 13 (18) |
| Median Age (range) | 67 (45–77) | 66 (46–81) |

| Treatment       | n  | %  | n  | %  | p  |
|-----------------|----|----|----|----|----|
| Sorafenib group | 31 | 53 | 6  | 46 | 0.635 |
| Non Sorafenib group | 27 | 47 | 7  | 54 |

| Gender          | n  | %  | n  | %  | p  |
|-----------------|----|----|----|----|----|
| Male            | 32 | 55 | 9  | 69 | 0.354 |
| Female          | 26 | 45 | 4  | 31 |

| Disease extent  | n  | %  | n  | %  | p  |
|-----------------|----|----|----|----|----|
| Locally advanced | 20 | 34 | 5  | 38 | 0.786 |
| Metastatic      | 38 | 66 | 8  | 62 |

| Primary tumour location | n  | %  | n  | %  | p  |
|-------------------------|----|----|----|----|----|
| Head                    | 31 | 53 | 8  | 62 | 0.596 |
| Other                   | 27 | 47 | 5  | 38 |

| Biliary stenting        | n  | %  | n  | %  | p  |
|-------------------------|----|----|----|----|----|
| Yes                     | 5  | 9  | 2  | 15 | 0.459 |
| No                      | 53 | 91 | 11 | 85 |

| Metastatic sites location | n  | %  | n  | %  | p  |
|----------------------------|----|----|----|----|----|
| Hepatic                    | 24 | 41 | 6  | 46 | 0.753 |
| Extra-hepatic              | 34 | 59 | 7  | 54 |

| Metastatic site number | n  | %  | n  | %  | p  |
|------------------------|----|----|----|----|----|
| 1                      | 51 | 88 | 9  | 69 | 0.119 |
| 2                      | 5  | 9  | 2  | 15 |
| 3                      | 2  | 3  | 1  | 8  |
| ≥4                     | 0  | 0  | 1  | 8  |

| Karnofsky PS            | n  | %  | n  | %  | p  |
|-------------------------|----|----|----|----|----|
| <70                     | 16 | 28 | 4  | 31 |
| ≥70                     | 42 | 72 | 9  | 69 |
ACKNOWLEDGMENTS

No acknowledgements.

CONFLICTS OF INTEREST

Prof. Cascinu, Prof. Scartozzi, Dr. Sobrero, Dr. Boni, Dr Labianca declare honoraria for speaking and advisory board.

All the other authors have no conflict of interest to declare.

The manuscript has not been published previously, and is not under consideration, in whole or in part, for publication elsewhere.

The manuscript is approved by all Authors.

GRANT SUPPORT

No grant support.

REFERENCES

1. Holbrook JJ, Liljas A, Steindel SJ. Lactate dehydrogenase. Boyer PD. The enzymes. (3rd)1975; New York Academic Press XI:191–192.
2. Markert CL. Lactate dehydrogenase isozymes: dissociation and recombination of subunits. Science. 1963; 140:1329–30.
3. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002; 64:993–8.
4. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000; 88:1474–80.
5. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci US. 1997; 94:8104–9.
6. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999; 15:551–78.
7. Scartozzi M, Falloppi L, Bianconi M, Giampieri R, Maccaroni E, Bittoni A, Del Prete M, Loretelli C, Belvederesi L, Svegliati Baroni G, Cascinu S. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One. 2012; 7:e32653.
8. Falloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C, D’Anzeo M, Benedetti A, Cascinu S. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014; 14:110.
9. Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Falloppi L, Bianconi M, Galizia E, Loretelli C, Belveder esi L, Bittoni A, Cascinu S. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012; 106:799–804.
10. Fiume L, Vettrai n M, Manerba M, Di Stefano G. Inhibition of lactate dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. Pharmacol Res. 2011; 63:328–34.
11. Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, Ferrari D, Barni S, Ati tini E, Zagonel V, Caprioni F, Villa F, Mosconi S, et al. Sorafenib does not improve activity of chemotherapy in advanced pancreatic cancer. A GISCAD randomized phase II study. Dig Liver Dis. 2014; 46:182–6.
12. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403–2413.
13. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362:1605–1617.
14. Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010; 28:3605–3610.
15. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28:3617–3622.
16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawka P, Walde D, Wolff RA, Campos D, Lim R, Ding K, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960–1966.
17. Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013; 49:2633–2642.
18. Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012; 23:2799–805.

19. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL. Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. Clin Cancer Res. 2011; 17:4892–900.

20. Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol. 2010; 16:4084–8.

21. Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol. 2008; 15:2336–44.

22. Kohles N, Nagel D, Jungst D Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing chemoembolization therapy. Tumour Biol. 2012; 33:33–40.

23. Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011; 29:2004–10.

24. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, et al. Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. J Clin Oncol. 2011; 29:1997–2003.